Highlights
- Stock gains nearly 4% intraday, approaching its 52-week high levels.
- Outperforms NIFTY 500 across short-term and long-term return periods.
- Trading activity remains elevated with higher volumes and liquidity indicators.
Shares of Natco Pharma (NSE:NATCOPHARM) were trading at Rs 1,067.90 on April 7, 2026, up 3.83% from the previous close of Rs 1,028.55. The stock opened at Rs 1,023.00 and moved between Rs 1,008.00 and Rs 1,077.00 during the session, hitting its 52-week high. The VWAP stood at Rs 1,062.00, reflecting trading activity close to the day’s average price.
Strong Performance Across Timeframes
Natco Pharma has delivered higher returns than the NIFTY 500 index across multiple periods. Over the past week, the stock gained 9.63%, compared to 3.11% for the index.
In the one-month period, it rose 4.74% while the index declined 5.85%. Year-to-date, the stock is up 20.24%, contrasting with an 11.47% decline in the broader market.
Over a one-year timeframe, the stock delivered 39.45% returns versus 5.27% for the index. On a three-year basis, it gained 84.71%, exceeding the index’s 43.41% return. However, the five-year performance of 26.18% trails the index’s 69.58%.
Trading Activity and Market Capitalisation
The stock recorded traded volumes of 13.79 lakh shares, translating into a traded value of Rs 146.45 crore. Natco Pharma’s total market capitalisation stood at Rs 19,127.14 crore, with a free float market capitalisation of Rs 9,554.04 crore.
The impact cost was low at 0.04, indicating relatively stable liquidity conditions. Deliverable quantity accounted for 29.90% of traded volume, suggesting a higher share of intraday trades.
Volatility and Price Band
Natco Pharma operates within a 20% price band, with an upper limit of Rs 1,234.25 and a lower limit of Rs 822.85. The stock recorded daily volatility of 2.39%, while annualised volatility stood at 45.66%, indicating relatively higher price fluctuations over time.
Financial Snapshot
For the quarter ended December 31, 2025, the company reported total income of Rs 70,540.00 lakh. Profit before tax was Rs 16,110.00 lakh, while net profit stood at Rs 15,130.00 lakh. Earnings per share (EPS) for the quarter was Rs 8.46. The results were reported on a consolidated and unaudited basis.
Key Risks
- Revenue dependence on specific products may impact earnings consistency.
- Regulatory changes in pharmaceutical markets could affect operations.
- Higher volatility levels may lead to sharp price fluctuations.
- Competitive pressure in generic drug segment could influence margins.
FAQs
- Why is Natco Pharma stock rising recently?
The stock is gaining momentum with strong returns across timeframes and is currently trading near its 52-week high levels. - How does Natco Pharma compare with NIFTY 500 returns?
It has outperformed the index across one-week, one-month, year-to-date, and one-year return periods based on available data. - What do current volatility levels indicate for the stock?
Higher volatility suggests increased price fluctuations, reflecting active trading and changing market sentiment around the stock.